Sun Pharmaceutical Industries Initiates Class II Recall of Mesalamine Tablets Due to Microbial Contamination
Sun Pharmaceutical Industries Inc. has initiated a Class II recall of 10,690 bottles of Mesalamine Delayed-Release Tablets, USP 1.2 g, due to microbial contamination found in manufacturing equipment. This event, stemming from their Dadra, India facility, necessitates immediate assessment by procurement, supply chain, and regulatory teams to mitigate potential supply disruptions and ensure patient safety for this critical inflammatory bowel disease medication.
FDA Class II Recall: Microbial Contamination Prompts Sun Pharma Mesalamine Withdrawal
Sun Pharmaceutical Industries Inc. has initiated a voluntary Class II recall, designated D-0268-2024, for multiple lots of its Mesalamine Delayed-Release Tablets, USP 1.2 g. This critical action, reported on January 31, 2024, impacts 10,690 bottles distributed nationwide across the USA. The primary reason for this recall is a significant Current Good Manufacturing Practice (CGMP) deviation: microbial contamination was identified in stagnant water within the duct of the manufacturing equipment at their facility in Dadra, India. For procurement directors, this means an immediate disruption to the supply of a key drug used in the management of inflammatory bowel conditions, requiring rapid assessment of existing stock and potential shortages. Regulatory affairs heads must understand that a Class II classification, while indicating a remote probability of serious adverse health consequences, still signals a serious quality system breakdown that demands robust corrective action. This event underscores the imperative for stringent quality control throughout the manufacturing process to safeguard product integrity and patient safety, directly impacting market availability and brand trust.
Sun Pharma's India Manufacturing Facility Under Scrutiny for Mesalamine Production
The affected Mesalamine Delayed-Release Tablets, USP 1.2 g (NDC 63304-175-13), were manufactured by Sun Pharmaceutical Industries Limited at Survey No. 259/15, Dadra-396 191 (U.T. of D & NH), India, and distributed by Sun Pharmaceutical Industries, Inc. from Cranbury, NJ 08512. The recall was initiated by the Princeton, NJ-based entity. This highlights the intricate global supply chain dynamics where a significant portion of pharmaceutical manufacturing for the U.S. market occurs overseas. For supply chain VPs, this incident from an Indian facility emphasizes the inherent risks associated with international sourcing, including varying regulatory oversight and potential communication challenges. The detection of microbial contamination in manufacturing equipment at an overseas plant necessitates a heightened level of due diligence and continuous monitoring of foreign manufacturing sites. Businesses relying on products from this specific Dadra facility, or indeed any of Sun Pharma's global network, must now reassess their risk profiles related to geographic manufacturing locations and quality control standards. This event directly impacts the reliability of supply and demands a re-evaluation of supplier qualification processes.
Supply Chain Exposure: Nationwide Impact of Mesalamine Recall in the USA
The recall of Mesalamine Delayed-Release Tablets, USP 1.2 g, affects specific lots: DNE0875A (Exp. 01/31/2025), DNE0876A, DNE0877A, DNE1080A, DNE1081A (all Exp. 02/28/2025), and DNE1147A, DNE1148A (all Exp. 03/31/2025). With 10,690 bottles distributed nationwide in the USA, this recall presents a tangible supply chain exposure for healthcare providers and pharmacies. For procurement directors, this means an immediate need to quarantine affected lots and identify unaffected inventory. The nationwide distribution pattern suggests a broad impact, potentially leading to localized or regional shortages of Mesalamine, a drug critical for patients with ulcerative colitis and Crohn's disease. Business development executives should recognize this as an opportunity for competitors with robust quality systems and alternative Mesalamine supplies to gain market share. Furthermore, companies that rely on Sun Pharma as a contract manufacturer or API supplier for related products must conduct an immediate risk assessment to determine if similar quality control vulnerabilities exist within their own supply agreements, potentially impacting their product lines and market commitments.
Mitigating Supply Risk: Identifying Alternative Mesalamine Suppliers
Given the Class II recall of Mesalamine Delayed-Release Tablets from Sun Pharmaceutical Industries, procurement teams must urgently explore and qualify alternative suppliers to ensure continuity of supply for this vital aminosalicylate medication. While specific alternative suppliers are not detailed in the available intelligence, the market for generic Mesalamine includes several established manufacturers. Supply chain VPs should initiate a rapid assessment of potential new partners, focusing on those with a proven track record of CGMP compliance and robust quality management systems. Key considerations include geographic diversity of manufacturing sites to mitigate single-region risks, regulatory history with agencies like the FDA, and the capacity to meet U.S. market demand. The qualification timeline for a new pharmaceutical supplier can be extensive, often spanning several months for full regulatory approval and commercial readiness. Therefore, proactive engagement with multiple potential suppliers, including those with existing FDA approvals for Mesalamine, is paramount to minimize future supply chain vulnerabilities and maintain patient access to essential therapies.
Sun Pharmaceutical Industries: Implications for Supplier Quality Audits
While the provided intelligence does not detail a specific history of prior FDA Warning Letters or 483 observations for Sun Pharmaceutical Industries, this Class II recall for microbial contamination represents a significant regulatory event. For regulatory affairs heads and procurement directors, this incident should trigger an immediate review of all existing supplier agreements with Sun Pharma, particularly for products manufactured at the Dadra, India facility. The identification of microbial contamination in manufacturing equipment indicates a fundamental breakdown in environmental monitoring or sanitation protocols, which are core CGMP requirements. This signals a need for enhanced supplier quality audits, moving beyond routine checks to more intensive, unannounced inspections focusing on aseptic processing, water systems, and equipment maintenance. The absence of specific historical data in this context does not diminish the severity of the current finding; rather, it emphasizes the importance of continuous vigilance and independent verification of quality systems for all third-party manufacturers to protect supply chain integrity and product quality.
Remediation and Future Outlook: Sun Pharma's Path to Compliance
As a voluntary, firm-initiated Class II recall, Sun Pharmaceutical Industries Inc. is now responsible for a comprehensive remediation strategy to address the microbial contamination identified at its Dadra, India manufacturing facility. For regulatory affairs teams, this means closely monitoring Sun Pharma's corrective and preventive actions (CAPA) plan, which must include a thorough root cause analysis, implementation of enhanced cleaning and sanitization protocols, and validation of equipment modifications to prevent recurrence. The FDA will expect detailed documentation of these efforts, and a follow-up inspection of the Dadra facility is highly probable to verify the effectiveness of the remediation. Failure to adequately address these CGMP deviations could escalate regulatory actions, potentially leading to an FDA Import Alert on products from this facility, which would severely impact U.S. market access. Supply chain VPs must factor this potential for future regulatory action into their risk assessments, understanding that the stability of Mesalamine supply, and potentially other products from this site, hinges on Sun Pharma's swift and effective return to full compliance. Proactive communication and transparency from Sun Pharma will be crucial in rebuilding trust with its partners and the FDA.